Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$7.96 USD

7.96
249,847

+0.01 (0.13%)

Updated Apr 26, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (141 out of 252)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Veradigm (MDRX) to Acquire AI Service Provider ScienceIO

by Zacks Equity Research

Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

by Zacks Equity Research

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence

by Zacks Equity Research

Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.

Braze, Inc. (BRZE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Braze, Inc. (BRZE) delivered earnings and revenue surprises of 61.54% and 5.89%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?

Veradigm's (MDRX) New Offering to Enhance Patient Engagement

by Zacks Equity Research

Veradigm's (MDRX) latest solution is likely to offer its clients the right payment option to each individual patient through the right communication channel.

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

by Zacks Equity Research

Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

by Zacks Equity Research

Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

by Zacks Equity Research

Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.

Vivid Seats Inc. (SEAT) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Vivid Seats Inc. (SEAT) delivered earnings and revenue surprises of 233.33% and 10.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yext (YEXT) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Yext (YEXT) delivered earnings and revenue surprises of 60% and 0.90%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Sprinkler (CXM) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Sprinkler (CXM) delivered earnings and revenue surprises of 500% and 2.68%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Veradigm (MDRX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.

Kyndryl Holdings, Inc. (KD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kyndryl Holdings, Inc. (KD) delivered earnings and revenue surprises of 82.93% and 2.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

by Zacks Equity Research

Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.

Earnings Preview: R1 RCM Inc. (RCM) Q1 Earnings Expected to Decline

by Zacks Equity Research

R1 RCM Inc. (RCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Veradigm (MDRX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.

Implied Volatility Surging for Veradigm (MDRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.

Implied Volatility Surging for Veradigm (MDRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.

What to Expect from Verisk Analytics' (VRSK) Q4 Earnings?

by Zacks Equity Research

Verisk Analytics' (VRSK) earnings and revenues are expected to have taken a hit by the disposition of parts of its energy and specialized market segments.

Shuvra Shankar Dey headshot

3 Service Stocks Poised to Beat Earnings Estimates in Q4

by Shuvra Shankar Dey

Here we pick three business service stocks, namely PagSeguro Digital (PAGS), Veradigm (MDRX) and TuSimple (TSP), which are likely to pull off earnings surprises this time around.

Green Dot (GDOT) to Report Q4 Earnings: What to Expect

by Zacks Equity Research

Green Dot's (GDOT) revenues and earnings seem to have suffered due to declining active accounts and increasing expenses.

Analysts Estimate TTEC Holdings (TTEC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

TTEC (TTEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will (MDRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

(MDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MDRX or VERI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MDRX vs. VERI: Which Stock Is the Better Value Option?

Syneos Health (SYNH) Signs New Partnership With Cryoport

by Zacks Equity Research

Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.